mProX™ Human MAP4K1 Stable Cell Line

Sub Cat	Product Name	Target Protein Species	Host Cell Type	Assay Types	Inquiry	Datasheet
S01YF-1122-KX1166	Magic™ Human HPK1(MAP4K1) in Vitro Assay	Human		Kinase Assay

Product Information

Target Protein

MAP4K1

Target Family

Kinases/Enzyme Drug Discovery Assays and Products

Target Protein Species

Human

Host Cell Type

MV4-11; CHO-K1; HEK293

Target Classification

Kinase Cell Lines

Target Research Area

Auditory and Otology Research

Related Diseases

Melnick-Needles Syndrome. Among its related pathways are TGF-Beta Pathway and Angiopoietin-like protein 8 regulatory pathway.

Gene ID

11184

UniProt ID

Q92918

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

The MAP4K1 gene in humans encodes the protein kinase known as mitogen-activated protein kinase kinase kinase 1. Another name for it is Hematopoietic Progenitor Kinase 1 (HPK1). It has been demonstrated that the protein contributes to JNK activation. Within the RIG-I-like receptor (RLR) signaling pathway, MAP4K1 functions as a negative regulator. Prior research established that MAP4K1, a member of the Ste20-like serine/threonine kinases, was a key modulator of adaptive immunity through the downregulation of T-cell receptor (TCR) and B-cell receptor (BCR) signaling. Its function in controlling innate immunological signaling against viruses is still unknown, though. The customized MAP4K1 stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat Kathleen

The human MAP4K1 overexpression cell line is easy to work with and consistently provides reliable results. Jan 30 2020

chat Verified Customer

chat Sharon

The MAP4K1 cell line was easy to use, saving me valuable time in the lab. Aug 17 2020

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 Relative mRNA expression level of MAP4K1 in nine AML cell lines.

The MAP4K1 expression levels in nine AML cell lines were ascertained by western blot and RT-qPCR. Following investigation, MAP4K1 overexpression was selected for MV4-11, and MAP4K1 knockdown was performed on THP-1 and MV4-11 R50 cell lines.

Ref: Ling, Qing, et al. "MAP4K1 functions as a tumor promotor and drug mediator for AML via modulation of DNA damage/repair system and MAPK pathway." EBioMedicine 69 (2021).

Pubmed: 34166980

DOI: 10.1016/j.ebiom.2021.103441

Research Highlights

This work shows that MAP4K1 independently predicts the prognosis of AML and modulates HHT resistance. Additionally, new approaches to treating resistant and refractory AML are revealed by comprehending the regulation mechanism of MAP4K1.
Ling, Qing, et al. "MAP4K1 functions as a tumor promotor and drug mediator for AML via modulation of DNA damage/repair system and MAPK pathway." EBioMedicine 69 (2021).
Pubmed: 34166980 DOI: 10.1016/j.ebiom.2021.103441

In this work, strong small molecule inhibitors of MAP4K1 are identified, which may represent new therapeutic targets capable of eliciting a powerful immune response when used alone or in conjunction with authorized checkpoint inhibitors.
Faia, Kerrie, et al. "MAP4K1 inhibition enhances immune cell activation and anti-tumor immunity in preclinical tumor models." Cancer Research 81.13_Supplement (2021): 1717-1717.